echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > BJH: Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone triple therapy in patients with RRMM who have received two or more drugs

    BJH: Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone triple therapy in patients with RRMM who have received two or more drugs

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multiple myeloma (MM) occurs due to clonal proliferation of malignant plasma cells in the bone marrow and/or extramedullary sites, and there is an unmet need for the treatment of patients with drug-resistant/refractory multiple myeloma (MM)


    Multiple myeloma (MM) occurs due to clonal proliferation of malignant plasma cells in the bone marrow and/or extramedullary sites, and there is an unmet need for the treatment of patients with drug-resistant/refractory multiple myeloma (MM)


    The researchers recruited 28 patients between February 2020 and December 2021


    Figure 1: Schematic diagram of patient placement


    Figure 1: Schematic diagram of patient placement


    Table 1: Response to PBD treatment


    Table 1: Response to PBD treatment


    Patients received a median of 3 previous medications, and 85.


    Figure 2: (A) Progression-free survival (n = 28)


    Figure 2: (A) Progression-free survival (n = 28)


    Table 2: Dose reductions and discontinuations


    Table 2: Dose reductions and discontinuations


    An ORR of 57.


    The study suggests that bendamustine, pomalidomide, and dexamethasone may be a new combination for the treatment of heavily pretreated lenalidomide-refractory myeloma populations


    Original source:

    Original source:

    Kumar, S ,Sharma, A ,Malik, PS ,  Gogia, A ,  Pathak, N ,  Sahoo, RK , et al.


    Kumar, S ,  Sharma, A ,  Malik, PS ,  Gogia, A ,  Pathak, N ,  Sahoo, RK , et al.
      Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial .
      Br J Haematol .
      2022 ;  00 :  1 –  10 .
    https://doi.
    org/10.
    1111/bjh.
    18200.
    Kumar, S Sharma, A Malik, PS Gogia, A Pathak, N Sahoo, RK Bendamustine in combination with pomalidomide and dexamethasone in relapsed/ refractory multiple myeloma: A phase II trialBr J Haematol 2022 00 1 10

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.